Results 161 to 170 of about 43,933 (287)

Medical marijuana utilization in gynecologic cancer patients. [PDF]

Gynecol Oncol Rep, 2021
Fehniger J, Brodsky AL, Kim A, Pothuri B.   +3 more
europepmc   +1 more source

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source

Medical Marijuana in the Mid-Atlantic Region. [PDF]

Dela J Public Health
Khan M, Agarwal V.
europepmc   +1 more source

Associations Among Marijuana Use, Occurrence of Major Depressive Episodes, and Health Insurance Status

Introduction: Despite the high prevalence of mental illnesses, more than half of adults with a mental health illness do not receive treatment, with 24.7% of affected adults reporting an unmet need for treatment in 2019.
Ali, Syeda
core   +1 more source

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for a Prospective Cohort Study. [PDF]

JMIR Res Protoc
Robinson KR, Seeger SD, Nave L, Mejia M, Vander Meulen M, Rashid A, Mickle AM, Sibille KT, Li Z, Przkora R, Schmidt S, Lo MC, Cook RL, Wang Y.   +13 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Understanding the acceptance of medical marijuana among Malaysian adults: a cross-sectional online survey. [PDF]

BMJ Open
Rahman AB, Naserrudin NA, Seman Z, Zin ZM, Dapari R, Hassan MR, Rashid AA, Dahaban MUM, Jahaya NH, Balamurugan H, Krishnan M.   +10 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Medical Marijuana and Treatment Personalization: The Role of Genetics and Epigenetics in Response to THC and CBD. [PDF]

Genes (Basel)
Kalak M, Brylak-Błaszków A, Błaszków Ł, Kalak T.   +3 more
europepmc   +1 more source